Validation of New Prognostic biomarkerRs in Patients With cirrhOsis diScharged After a hosPitalization Due to acutE deCompensation or acuTe-on-chronic Liver Failure
Status: Recruiting
Location: See all (9) locations...
Study Type: Observational
SUMMARY
The study aims to test the effectiveness of new biomarkers (measurable molecules in our body) in predicting the health outcome of patients with liver cirrhosis discharged from the hospital after a serious complication of the disease
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Age between 18 and 80 years.
• Patients with decompensated cirrhosis admitted to hospital due to AD according to the EASL-CLIF criteria (rapid onset of ascites, hepatic encephalopathy, portal hypertensive- related gastrointestinal bleeding, bacterial infection, or any combination of these), including those who presented ACLF during hospitalization.
• Recovery from AD and expected to be discharged within the next 48 hours.
Locations
Other Locations
France
Hospital Beaujon
RECRUITING
Clichy
Germany
University Hospital, Aachen
RECRUITING
Aachen
Universitätsklinikum Münster
RECRUITING
Münster
Italy
IRCCS Azienda Ospedaliero Universitaria di Bologna Policlinico di S.Orsola
RECRUITING
Bologna
A.O.U. Città della Salute e della Scienza di Torino
RECRUITING
Torino
Spain
Hospital Clinic de Barcelona
RECRUITING
Barcelona
Hospital Universitari Vall d'Hebron Research Institute
RECRUITING
Barcelona
Hospital Universitario Ramon y Cajal
RECRUITING
Madrid
United Kingdom
Royal Free Hospital
NOT_YET_RECRUITING
London
Contact Information
Primary
Anna Bosch
anna.bosch@efclif.com
+34 93 227 14 03
Backup
Cristina Sánchez-Garrido
cristina.sanchez@efclif.com
Time Frame
Start Date: 2025-03-01
Estimated Completion Date: 2026-09-30
Participants
Target number of participants: 189
Treatments
Patients with Decompensated Liver Cirrhosis
Patients eligible for this study will be patients with decompensated cirrhosis expected to be discharged from the hospital within 48 hours after an index admission for AD according to the EASL-CLIF criteria
Related Therapeutic Areas
Sponsors
Leads: European Foundation for Study of Chronic Liver Failure
Collaborators: Universität Münster, Hospital Universitari Vall d'Hebron Research Institute, A.O.U. Città della Salute e della Scienza, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Beaujon Hospital, Hospital Universitario Ramon y Cajal, Hospital Clinic de Barcelona, Barcelona, Spain, University Hospital, Aachen